was successfully added to your cart.

Research News

Homepage NewsResearch News
September 13, 2017

New trial for a ‘molecular band-aid’ to help DMD hearts and lungs

Several DMD organizations recently teamed up to fund a Phase 2 clinical trial of a new therapy for Duchenne muscular dystrophy (DMD) – Carmeseal-MD. Carmeseal-MD…
Read More
Homepage NewsResearch News
July 22, 2017

What’s next for exon skipping, the personalized medicine that produces dystrophin?

The first exon-skipping treatment for DMD was approved last year, but this is no time to rest on our laurels. We're funding the development of…
Read More
Stem cells isolated from mouse muscle fibers are grown into myotubes in a culture dish. These structures have muscle fiber-like properties useful for testing drugs like NEIs.
Homepage NewsResearch News
April 28, 2017

What are neutrophil elastase inhibitors, and why do they hold promise for DMD?

Charley's Fund, Duchenne UK, and Joining Jack recently announced a collaborative grant to Dr. Dada Pisconti of the University of Liverpool in England. With this…
Read More
Research News
April 28, 2017

Charley’s Fund, Duchenne UK, and Joining Jack join forces on grant to investigate new approach to treat DMD

One of our core values is LEVERAGE. So we are very excited to join forces with partners across the Pond to fund a new research…
Read More
EIM in Action
Homepage NewsResearch News
March 10, 2017

Promising new data about Electrical Impedance Myography for DMD

Harvard doctor and scientist Seward Rutkove recently published new data about Electrical Impedance Myography, a non-invasive outcome measure for Duchenne muscular dystrophy and other muscle diseases. Charley's…
Read More
Homepage NewsNewsResearch News
September 19, 2016

FDA grants accelerated approval to first drug for Duchenne muscular dystrophy

The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys…
Read More
Research News
June 22, 2016

Update on the HT-100 program

Earlier this week at the annual PPMD Connect Conference in Orlando, Akashi Therapeutics CMO Dr. Diana Escolar presented an update on the HT-100 program. "We…
Read More
Homepage NewsResearch News
May 22, 2016

We remain active on other medical research fronts

While we aggressively advocate for the approval of eteplirsen, we remain active on other medical research fronts. It's important to remember that eteplirsen helps 13%…
Read More